Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, ... it has received the second $1.0M tranche under ... Research (SBIR) grant valued at up to $3.0 ... aerosolized KL4 surfactant as a potential medical countermeasure ...  Discovery Labs was awarded an initial $1.0 million ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... modern world, largely due to properties that render the ... One of their most useful qualities, however - the ... stress - is also one of the most puzzling., ... to change shape to absorb energy rather than breaking ...
... November 27 Arpida,announced today that it is refocusing all ... says this is to be seen as a,consequence of the ... board on 20 November 2008 regarding the,approval of Iclaprim in ... the context of the FDA advisory board,s recommendation the Arpida,board ...
... market and business intelligence company, the biofuel market is estimated at ... of approximately 85% bioethanol and 15% biodiesel. Bioethanol is produced and ... Europe is the world leader in biodiesel production and this fuel ... ...
Cached Biology Technology:Fast molecular rearrangements hold key to plastic’s toughness 2Fast molecular rearrangements hold key to plastic’s toughness 3Arpida to Restructure and Focus on Key Projects 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 4
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... gold purify the air when they are lit up ... experts have discovered. Associate Professor Zhu Huai Yong, ... that glaziers in medieval forges were the first nanotechnologists ... Professor Zhu said numerous church windows across ...
... of the drugs given to many men during their fight ... grow, researchers have found. The findings were published online this ... of the National Academy of Sciences . The results ... decades. Hormone therapy, a common treatment for men with advanced ...
... (MRI) isn,t just for capturing detailed images of the ... developed by Carnegie Mellon University scientist Eric Ahrens, MRI ... cell populations of interest in the living body. ... as immune cells, will greatly aid the study and ...
Cached Biology News:Air-purifying church windows early nanotechnology 2Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... (HDAC) Antibody Sampler Kit Kit Includes: ... #2062, 40 ul Histone Deacetylase 3 (HDAC3) ... 4 (HDAC4) Antibody, Catalog #2072, 40 ul ... 40 ul Histone Deacetylase 6 (HDAC6) Antibody, ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: